sprite-preloader
Anzeige
Mehr »
Samstag, 20.04.2019 Börsentäglich über 12.000 News von 604 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2AH3F ISIN: DK0060732477 Ticker-Symbol: ONQ 
Aktie:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOLOGY VENTURE A/S Chart 1 Jahr
1-Woche-Intraday-Chart
ONCOLOGY VENTURE A/S 1-Woche-Intraday-Chart

Aktuelle News zu ONCOLOGY VENTURE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
DiNasdaq Stockholm AB: Trading in Unit rights (UR) and Paid subscription units (BTU) in Oncology Venture A/S (141/19)11
As from April 17, 2019, unit rights (UR) issued by Oncology Venture A/S will be traded on First North. Trading will continue until April 29, 2019. Instrument: Unit rights ...
► Artikel lesen
ONCOLOGY VENTURE Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!

► Artikel lesen
09.04.Oncology Venture - A new regulatory strategy for dovitinib2
Oncology Venture (OV) recently revealed its new regulatory strategy and clinical development plan for one of highest priority assets: dovitinib. OV will seek marketing approval for dovitinib based on...
► Artikel lesen
08.04.Oncology Venture A/S: Oncology Venture invites to a webcast April 8 at 16:306
Investor News Following the presentation of Oncology Venture's prospectus as part of the rights issue announced on Friday, April 5, the company invites to a webcast. At the webcast, Oncology...
► Artikel lesen
05.04.Oncology Venture A/S: Oncology Venture hereby publishes a prospectus regarding the rights issue starting on April 17, 2019-

► Artikel lesen
05.04.Oncology Venture A/S: The Board of Oncology Venture resolves to conduct a rights issue of new shares-

► Artikel lesen
04.04.Oncology Venture A/S: Minutes of Ordinary General Meeting-

► Artikel lesen
04.04.Oncology Venture A/S: Oncology Venture obtains option to in-license the European rights to the FDA approved ixabepilone3

► Artikel lesen
03.04.Oncology Venture A/S: Dovitinib regulatory strategy confirmed and new combination biomarker DRP PD1/PD-L1 + dovitinib developed. Oncology Venture engages ...-

► Artikel lesen
29.03.Oncology Venture A/S: Laboratory set up in Berlin and strategic collaboration with leading German and Danish cancer coorporative groups entered to develop ...-

► Artikel lesen
28.03.Oncology Venture - Rounding out a productive year of R&D2
Oncology Venture (OV) has ramped-up R&D with multiple trials moving forward. Its Phase II study of LiPlaCis in metastatic breast cancer (mBC) remains ongoing as it awaits FDA approval of the IDE/IND...
► Artikel lesen
22.03.Oncology Venture A/S: The observation status of Oncology Venture is removed-

► Artikel lesen
22.03.Nasdaq Stockholm AB: The observation status of Oncology Venture A/S is removed (106/19)1
On March 21, 2019, Nasdaq Stockholm AB decided that the shares in Oncology Venture A/S were to receive observation status with reference to material adverse uncertainty in respect of the company's financial...
► Artikel lesen
22.03.Oncology Venture A/S: Oncology Venture has established bridge loan facility-

► Artikel lesen
21.03.Nasdaq Stockholm AB: Oncology Venture A/S receives observation status (105/19)3
Yesterday, on March 20, 2019, Oncology Venture A/S published its annual report for 2018 with information on the company's financial situation. The current rules of First North state that a listed...
► Artikel lesen
20.03.Oncology Venture A/S: Oncology Venture publishes the Annual Report for 2018-

► Artikel lesen
15.03.Oncology Venture A/S: Oncology Venture receives guarantees and undertakings for a proposed rights issue-

► Artikel lesen
13.02.Oncology Venture - Multiple programme updates4
Edison Investment Research - Pharmaceuticals & healthcare - Oncology Venture: Oncology Venture (OV) continues to provide regular response data from its ongoing LiPlaCis Phase II trial in patients with...
► Artikel lesen
07.02.Oncology Venture A/S: Clinical update: Dovitinib DRP data mining successfully completed and new LiPlaCis data continues to support an FDA breakthrough designation strategy5
Press release Hoersholm, Denmark and Cambridge, MA, US, February 7, 2019 - Oncology Venture A/S ("OV" or "the Company") today provides a clinical update on its precision drug projects. Oncology...
► Artikel lesen
21.12.18Oncology Venture - FDA OKs 505(b)(2) pathway for LiPlaCis in mBC1
Edison Investment Research - Pharmaceuticals & healthcare - Oncology Venture: Oncology Venture (OV) recently announced that the FDA agreed the 505(b)(2) pathway is an appropriate route for LiPlaCis...
► Artikel lesen
18.12.18Communique from EGM in Oncology Venture A/S-

► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
ONCOLOGY VENTURE A/S-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten